Targeted delivery of gemcitabine to lung cancer cells via a hyaluronic acid-based nanoplatform

Key Points

• This research aims to improve lung cancer treatment through targeted delivery of gemcitabine using a nanoplatform.
• Developed a CD44-targeted nanoplatform (GEM@HA-(HAP/PSI)) for drug delivery.
• Employed a high drug-loading HAP core and HA–PSI shell for active targeting and pH-responsive release.
• Conducted in vitro and in vivo evaluations of antitumor effects.
• The nanoplatform demonstrated superior in vitro antitumor activity compared to conventional delivery methods.
• In vivo studies showed significant tumor suppression, indicating effective targeting to lung cancer cells.
• CD44-mediated endocytosis facilitated enhanced drug uptake and release.